Castle Biosciences, Inc.CSTLNASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank84
5Y CAGR+14.2%
Year-over-Year Change
Year-over-year free cash flow growth rate
5Y CAGR
+14.2%/yr
Long-term compound
Percentile
P84
Within normal range
vs 5Y Ago
1.9x
Solid growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 153.26% |
| Q3 2025 | -32.54% |
| Q2 2025 | 207.26% |
| Q1 2025 | -164.15% |
| Q4 2024 | -0.96% |
| Q3 2024 | -9.64% |
| Q2 2024 | 217.40% |
| Q1 2024 | -208.06% |
| Q4 2023 | 478.57% |
| Q3 2023 | 132.69% |
| Q2 2023 | 72.82% |
| Q1 2023 | -269.55% |
| Q4 2022 | -7.23% |
| Q3 2022 | 30.21% |
| Q2 2022 | 52.34% |
| Q1 2022 | -494.23% |
| Q4 2021 | 47.96% |
| Q3 2021 | 3.96% |
| Q2 2021 | -67.79% |
| Q1 2021 | -329.93% |
| Q4 2020 | 79.04% |
| Q3 2020 | -141.39% |
| Q2 2020 | 1663.91% |
| Q1 2020 | -118.11% |
| Q4 2019 | 607.07% |
| Q3 2019 | 94.87% |
| Q2 2019 | -71.20% |
| Q1 2019 | 132.49% |
| Q4 2018 | -63.59% |
| Q3 2018 | 59.50% |
| Q2 2018 | -91.26% |
| Q1 2018 | 0.00% |